Navigation Links
Fate Therapeutics Announces First Patient Treated in Phase 1b Clinical Trial of FT1050 for Hematopoietic Stem Cell Support
Date:5/27/2009

comes but also allow more patients to receive timely treatments.

About Fate Therapeutics, Inc.

Fate Therapeutics is interrogating adult stem cell biology and applying induced pluripotent stem (iPS) cell technology to develop Stem Cell Modulators (SCMs), small molecule or biologic compounds that guide cell fate for therapeutic purposes. Fate's approach has broad therapeutic potential in areas such as regenerative medicine, hematological diseases, metastatic cancer, traumatic injury and degenerative diseases. In addition, Fate Therapeutics and Stemgent have formed an alliance - Catalyst - a collaborative program to provide its partners with first access to the most advanced induced pluripotent stem (iPS) cell technologies for drug discovery and development. Fate Therapeutics is headquartered in La Jolla, CA. For more information, please visit http://www.fatetherapeutics.com.


'/>"/>
SOURCE Fate Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
3. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
4. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
5. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
6. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
7. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
8. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
9. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
10. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
11. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)...  MiMedx Group, Inc.  (NASDAQ: MDXG ... patent-protected regenerative biomaterials and bioimplants processed from human ... initial Investigational New Drug ("IND") application with the ... The IND submission, which was filed yesterday, July ... certain indications of its micronized allografts towards targeted ...
(Date:7/23/2014)... 2014  Dompe, a leader in R&D for new therapeutic ... (Recombinant Human Nerve Growth Factor) has been designated as an ... The candidate drug, developed by the research ... the treatment of neurotrophic keratitis, a degenerative corneal disease that ... is currently without a cure. This is the second orphan ...
(Date:7/23/2014)... , July 23, 2014 Research ... the "Prepackaged Medical Kits and Trays - ... offering. http://photos.prnewswire.com/prnh/20130307/600769 ... for Prepackaged Medical Kits and Trays in US$ ... Trays, Ophthalmic Custom Trays, Custom Basin Kits, Custom ...
Breaking Medicine Technology:MiMedx Files Its Initial Investigational New Drug Application 2MiMedx Files Its Initial Investigational New Drug Application 3Dompe announces the Food and Drug Administration (FDA) has granted orphan drug designation to its rhNGF-based treatment for neurotrophic keratitis 2Dompe announces the Food and Drug Administration (FDA) has granted orphan drug designation to its rhNGF-based treatment for neurotrophic keratitis 3Dompe announces the Food and Drug Administration (FDA) has granted orphan drug designation to its rhNGF-based treatment for neurotrophic keratitis 4Prepackaged Medical Kits and Trays - Global Strategic Business Report: Updated 2014 Report 2
... Sept. 30, 2011 Haemonetics Corporation (NYSE: ... quarter of its 2012 fiscal year on October 31, ... hold a webcast to discuss and answer questions about ... 31, 2011. Webcast Link: http://phx.corporate-ir.net/phoenix.zhtml?p=irol-eventDetails&c=72118&eventID=4204617 ...
... Sept. 29, 2011 Boston Scientific Corporation (NYSE: ... ( NE ural C ardiac T her A ... a prospective, randomized, international clinical feasibility study designed to assess ... heart failure patients.  The study will evaluate 96 patients with ...
Cached Medicine Technology:Boston Scientific Begins Enrollment in NECTAR-HF Clinical Trial 2Boston Scientific Begins Enrollment in NECTAR-HF Clinical Trial 3Boston Scientific Begins Enrollment in NECTAR-HF Clinical Trial 4
(Date:7/23/2014)... (PRWEB) July 23, 2014 Texas Physical ... physical therapists from their Westlake, Westgate, Liberty Hill, Parmer, ... the professional designation of Orthopaedic Certified Specialist (OCS) ... June. Adriana Juarez, PT, DPT, OCS, Tony Lauretta, PT, ... PT, DPT, OCS, Joseph Leech, PT, DPT, OCS, and ...
(Date:7/23/2014)... Ticket Down is reliable source for cheap ... at the Cotton Bowl. The 2014 Guinness International Champions Cup ... and Canada beginning on July 24. The tournament features teams ... A, English Premier League, and Superleague Greece. Among the teams ... Milan, Liverpool, AS Roma, and Real Madrid. The latter two ...
(Date:7/23/2014)... July 23, 2014 In his latest ... and drug treatment facility CEO Per Wickstrom explains why ... tells you that she or he has never failed ... out lying,” commented Per Wickstrom. “Failure is not the ... compliment to success, because it reveals opportunities and shifts ...
(Date:7/23/2014)... WEDNESDAY, July 23, 2014 (HealthDay News) -- Children and teens ... an early death in adulthood, a new study suggests. ... had a 50 percent greater risk of death during the ... of a parent, according to the report. Although the ... child,s later risk of premature death, it wasn,t designed to ...
(Date:7/23/2014)... AidJoy is delighted to announce that it ... on September 5, 2014 from 7:00 to 11:00 p.m. ... expected to attend this semi-formal event. , "We are elated ... six years," says Jess Dennis, Director of Operations and organizer ... this moment in AidJoy’s history before we launch into our ...
Breaking Medicine News(10 mins):Health News:Texas Physical Therapy Specialists Congratulates New Board Certified Specialists 2Health News:Texas Physical Therapy Specialists Congratulates New Board Certified Specialists 3Health News:Real Madrid vs. AS Roma Tickets Cotton Bowl Dallas, TX: Ticket Down Slashes Ticket Prices on all AS Roma vs. Real Madrid International Champions Cup Tickets 2Health News:Real Madrid vs. AS Roma Tickets Cotton Bowl Dallas, TX: Ticket Down Slashes Ticket Prices on all AS Roma vs. Real Madrid International Champions Cup Tickets 3Health News:Per Wickstrom’s Latest Blog Post Explains why Entrepreneurs Should Plan for Failure 2Health News:Parent's Death May Raise Risk of Early Death for Grown Children, Study Suggests 2Health News:AidJoy’s Inaugural Gala to be Held September 5, 2014 2
... antidepressant Lexapro permitted by Food and Drug Administration, U.S.// ... FDA to sell escitalopram, a generic immitator of the oral ... drug are retained by the Forest Labs till March 2012 ... This copyright is illogical as per Teva. ,Lundbeck, ...
... that volunteers distributing condoms in the province would no longer ... rates of teenage pregnancies//. The trust said that only authorized ... protection measure. ,"My concern is that child ... commented Dr Dean Marshall, deputy chairman of the BMA's Scottish ...
... statement has said that drug maker Cipla Ltd. has ... nevirapine// that is to be marketed in a tablet ... similar approval for ondansetron in the injection form. ... following chemotherapy or radiation therapy for cancer. The drug ...
... increased blood pressure. But according to a recent study ... in giving them an uninterrupted sleep at the same ... results were presented at the American Thoracic Society International ... person's physical health, and this study shows once again ...
... presented at the American Thoracic Society International Conference, it was ... in lower lung function. The study of 2,112 adolescents ages ... of vitamin D, the recommended amount for this age group. ... low dietary intake of vitamin D (157 IU or less ...
... it was found that amino acid, l-cysteine can prevent ... of the cancers occur// in the mouth, pharynx and ... drinking. This results in a strong exposure of the ... research group of Professor Mikko Salaspuro, University of Helsinki ...
Cached Medicine News:Health News:Sleep Apnea Patients Benefit from Breathing Mask 2Health News:Decreased Vitamin D Intake among Teens Results in Decreased Lung Function 2Health News:Finnish research: Cysteine Chewing Gum as a cure for cancers of the mouth 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: